Bausch Health Cos., Inc.

Paulson's investment strategies are all based on the same underlying investment philosophy of capital preservation and low correlation to the broad markets. They perform fundamental and legal analysis on investments, including reviews of company financials and review of legal documentation related to proposed investment opportunities. The firm's products are provided through collective investment vehicles, including both domestic partnerships and offshore private investment companies, and separately managed accounts that deploy all or a subset of the firm's investment strategies. Paulson's investment objective is to achieve positive excess returns through trading the securities and/or derivatives thereon of companies that are the subject of proposed changes in corporate structure or control such as tender offers, mergers, spin-offs, proxy contests, liquidations, recapitalizations, restructurings and bankruptcy reorganizations.

ValueAct Capital was initially formed in June 2000 to manage the capital of its three founders, along with the capital of a limited number of outside investors, in an investment strategy that combines intensive due diligence, a concentrated number of investments, and active, constructive involvement in the value creation at those investments. Today, with offices in San Francisco and Boston, ValueAct Capital manages more than $8.0 billion on behalf of some of the world's most respected institutional and individual investors. ValueAct Capital concentrates on acquiring significant ownership stakes in a limited number of companies that it believes are fundamentally undervalued. The investment team seeks to identify companies that are out of favor, or may be undergoing significant transition. Such companies may be temporarily mispriced for a variety of reasons, including perceived unfavorable industry conditions, poor business performance, changes in management or ownership, reorganizations, or other external factors. These conditions can often result in fundamentally "good" businesses that are available at depressed valuations. The goal in each investment is to work productively with management and/or the company's board to implement a strategy or strategies that maximize returns for all shareholders. ValueAct Capital is typically one of the largest independent shareholders at each of its core company investments and works in a constructive manner with management and/or the company's board to successfully implement strategies that generate superior returns on invested capital. The seven investment partners have extensive experience working effectively with portfolio companies as long-term large shareholders, and oftentimes as members of the companies' boards. At any given time, the portfolio consists of ten to eighteen core company investments, as well as a small "farm team" of additional investments in development.

CC&L is an active, fundamentals-based manager which offers a full range of balanced, Canadian and global equity, fixed income as well as alternative investment solutions through separate accounts or pooled funds, aiming to achieve positive, risk-adjusted long-term performance relative to client benchmarks. Their strategies include fixed-income, fundamental equity, quantitative equity, balanced, alternative and group neutral. Canadian equities are managed through both fundamental and quantitative approaches. Foreign equity solutions are managed through an integrated quantitative global framework. A fundamental process is used for fixed income mandates. CC&L employs both quantitative and fundamental techniques for its absolute return strategies. They conduct detailed, broad economic analysis as well as specific asset class, country, industry and individual security research. Their quantitative discipline involves extensive use of in-house databases, systems and proprietary risk models.

Co-Founder at Longitude Capital Management Co. LLC

Vant Investment Chair, Roivant Pharma at Roivant Sciences Ltd.